CEACAM5 and neoplasm: Zhang et al. (2017) performed a phase I clinical study of CAR-T therapy for CRC with high carcinoembryonic antigen expression. Of 10 patients, seven progressed while receiving prior treatment and remained stable. After CAR-T treatment, the condition of each remained unchanged. Two patients showed tumor shrinkage. In addition, Mandriani et al. showed that anti-SSTR CAR-T cells are highly effective target-dependent cytotoxic agents against a range of NET cell lines with different SSTR2/5 expression levels (Mandriani et al., 2022).